Managing bacterial burden whilst preserving surrounding tissue is essential. The SteriPlas delivers contact-free Premium Cold Plasma that has been investigated extensively across wound care and infection management. Our approach is supported by a substantial and continually growing body of published clinical evidence demonstrating the ability of the SteriPlas to reduce bacterial burden, support wound healing and improve outcomes across a wide range of challenging wounds.
This expanding evidence base includes studies involving complex wounds and device-related infections, highlighting the potential role of the SteriPlas as an important adjunctive treatment where infection control and tissue preservation are critical.
As LVAD use continues to grow globally, innovative evidence-based therapies will play an increasingly important role in improving patient outcomes.
Innovation begins by combining cutting-edge technology with robust clinical evidence.
Credit to the image: Dr Thomas Schlöglhofer, Medical University of Vienna